Gastrointestinal Cancer

Pathologists and laboratory professionals are key members of the multidisciplinary cancer care team, with roles in the diagnosis, testing, and management of diseases such as gastrointestinal cancer. As new evidence continues to emerge related to personalized testing, treatment, and reporting, ASCP is dedicated to helping you stay abreast of new findings to ensure accurate diagnoses and improve the standard of care for patients with gastrointestinal cancer.

Diagnostic Pitfalls and Challenges in Hepatocellular Carcinoma

This one-hour CME/CMLE credit-bearing case-based online module will provide the latest guidance to the laboratory team in providing the most accurate recommendations for testing as members of the multidisciplinary hepatocellular carcinoma (HCC) cancer treatment team.

This activity addresses the following topics:

  • Liver tissue acquisition
  • HCC diagnostic challenges
  • IHC and ISH staining techniques to resolve common differential diagnoses
  • HCC biomarkers

Faculty

Jingmei Lin, MD, PhD, FASCP, Professor and Director of GI and Liver Pathology, Department of Pathology and Laboratory Medicine, Indiana University

Rondell P. Graham, MBBS, Professor of Lab Medicine and Pathology, Head of Section of GI/Liver Pathology, Vice Chair of Test Development for the Department of Lab Medicine and Pathology, Mayo Clinic

Topics

hepatocellular carcinoma; gastrointestinal cancer

Online Module

Diagnostic Pitfalls and Challenges in Hepatocellular Carcinoma

Register Now

Biomarker Testing in Colorectal Cancer

This one-hour CME/CMLE credit-bearing activity will provide guidance to members of the laboratory team on how to develop and implement guideline-driven biomarker testing protocols for patients with metastatic colorectal cancer (mCRC).

This activity addresses the following topics:

  • NCCN guidelines for biomarker testing for patients with mCRC
  • Considerations to optimize fixation, IHC, and molecular testing in patients with mCRC
  • Techniques for optimizing the interpretation and communication of biomarker testing results
  • New and emerging therapies for patients with mCRC
  • The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

Faculty

Benjamin Swanson, MD, PhD, Associate Professor & Associate Director, Gastrointestinal Pathology Fellowship, University of Nebraska Medical Center

Wei Jiang, MD, PhD, Associate Professor & Director, Translational Research/Pathology Shared Resource of Sidney Kimmel Cancer Center, Thomas Jefferson University

Topics

Colorectal Cancer; Gastrointestinal Cancer; mCRC;

Online Module

Biomarker Testing in Colorectal Cancer

This project is provided by an educational grant from Pfizer.
Register Now

Online Tumor Board Simulation: Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community Practice

This 60-minute self-paced online tumor board will help pathologists and laboratory professionals, particularly those in community practice, gain deeper scientific knowledge and skills in diagnosing, testing, and treating patients with BRAF-mutant metastatic colorectal cancer (mCRC). Throughout the online tumor board simulation, learners will answer questions designed to help them carefully consider the nuances of each case, building their knowledge and skills related to the detection and optimal management of patients with BRAF-mutant mCRC.

Topics covered include the following:

  • NCCN guidelines for conducting biomarker testing, including BRAF testing, for patients with mCRC
  • The importance of conducting biomarker testing at the time of diagnosis
  • Considerations to optimize fixation and IHC and molecular testing for BRAF mutations in patients with mCRC
  • Interpretation and communication of BRAF testing results
  • Opportunities for improving turnaround time in molecular testing in mCRC, including current and emerging testing platforms
  • Clinicopathologic characteristics of BRAF-mutant mCRC
  • New and emerging therapies for patients with BRAF-mutant mCRC
  • The importance of effective communication and a team-based approach in the diagnosis and management of patients with mCRC to optimize evidence-based clinical decision-making

Faculty

Wei Jiang, MD, PhD, FASCP, Associate Professor, Director, Translational Research/Pathology, Shared Resource of Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

Atrayee Basu-Mallick, MD, Associate Professor, Medical Oncology, Jefferson Health/Jefferson University Hospitals, Philadelphia, PA

Topics

BRAFV600E; mCRC; Gastrointestinal Cancer

Credits

The activity offers 1.0 CME/CMLE credit.

Online Tumor Board Simulation

Optimizing Testing and Treatment of Patients with BRAFV600E-mutant mCRC in Community Practice

This activity is supported by educational grants from Lilly and Pfizer.
Register Now

Multidisciplinary Approach to Diagnosis and Biomarker Testing in Gastrointestinal Cancer

Recorded February 15, 2022

This 60-minute on-demand webcast highlights practice-changing developments in gastrointestinal biomarker testing and treatment, including new clinical data with immediate implications for patient care. Using a case-based approach, an expert GI pathologist and oncologist will help you learn optimal testing, interpreting findings, individualized treatment, and sequencing strategies for gastrointestinal cancers.

Topics include:

  • Biomarkers and the use of molecular testing to guide therapy selection in patients with advanced colorectal, pancreatic, biliary, gastric, esophageal, and gastroesophageal junction cancers, such as:
    • BRAF V600E, BRCA1/2, HER2/HER3, BRAF V600E, IDH1, and FGFR2
    • Tumor agnostic biomarkers, such as MMR/MSI, NTRK, and TMB
    • Emerging biomarkers
  • Emerging assays in GI cancers, such as liquid biopsy

Faculty

Wei Jiang, MD, PhD, FASCP, Associate Professor, Director, Translational Research/Pathology Shared Resource of Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

Atrayee Basu-Mallick, MD, Associate Professor, Medical Oncology, Jefferson Health/Jefferson University Hospitals, Philadelphia, PA

Topics

Gastrointestinal Cancer

Online Module

Multidisciplinary Approach to Diagnosis and Biomarker Testing in Gastrointestinal Cancer

Provided by American Society of Clinical Pathology in partnership with Clinical Care Options, LLC. Supported by educational grants from Pfizer Inc. and Seagen Inc.
Register Now